Moreover, both PTEN-deficiency or PARP inhibition in cancer cells activates the PAT pathway [13, 14] and inhibition of the PAT pathway has been demonstrated to sensitize cancer cells to PARPis [15, 16]. The gene discussed is PARP1; the disease is cancer.